Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics designed to restore synapses to improve the lives of patients, will present this week the results of ...
Scientists found that mouse memory circuits start with many connections and then become more selective over time.
For decades, Alzheimer’s research has centered on neurons, the brain cells that die as the disease progresses, and on the ...
UCB, a global biopharmaceutical company, today announced signing of a definitive agreement under which it would acquire Candid Therapeutics (Candid), a privately held clinical-stage biotechnology ...
A Colombian man carried one of the most aggressive genetic mutations known to cause early-onset Alzheimer’s disease. By all ...